Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 276 results for "cipla"

Cipla to acquire 100% stake in two US generic drug firms for $550 mn

Booster dose for Cipla’s US business

Ciplas decision to acquire two US-based generic drug makers InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc will benefit the former on three counts. One, the acquisition will help Cipla widen its footprint in the US and boost the companys revenues ... Business Line, 12 minutes ago
Cipla buys two US drug firms in $550 mn deal Business Standard, 3 hours ago

92 images for cipla

Business Line, 9 minutes ago
Businessworld India, 5 hours ago
Times of India, 12 hours ago
NDTV Profit, 7 hours ago
Business Line, 9 minutes ago, 12 hours ago
India Infoline, 12 hours ago
India Infoline, 13 hours ago
Money Today, 11 hours ago
India Infoline, 1 day ago
Businessworld India

Cipla Buys 2 Generic Drug Units In US For Rs 3,655 Crore

The Friday announcement lifted Cipla shares as high as 4 per cent to Rs 675 a unit to start with, the share price settled at 4.4 per cent lower at Rs 652 just before Friday closing, reports C H Unnikrishnan Indian generic drug maker Cipla said on ...
 Businessworld India5 hours ago Cipla shares gain on acquisition of 2 US generic firms for $550 million  Financial Express10 hours ago
Business Insider India

Another mega pharma deal! Cipla to buy Hyderabad-based Hetero Drugs for $550mn

Cipla is all set to expand its portfolio. And this includes buying of the American business of Hyderabad-based Hetero Drugs. Country's third-largest drug maker will buy Invagen and Camber, Hetero's wholly owned subsidiary, for about $550 million. ...
 Business Insider India6 hours ago Cipla set to buy American business of Hetero Drugs for $550 million  Times of India12 hours ago Cipla set to buy Hetero's US ops for $550 million  Times of India12 hours ago Cipla only Indian company contending for Kremers Urban  DNA2 weeks ago

Give bull market another chance; bullish Cipla: Jai Bala

Jai Bala of 1857 Advisors says Bank Nifty's key level will be 15,500. He is bullish on SBI, subject to stocks staying above Rs 210 and believes FMCG space to support market, Hindustan Unilever being his top pick.
 Money Control8 hours ago Cipla may go above Rs 800: Jai Bala  MSN News US4 days ago

Hetero buy will boost Cipla's US ops in next 2-3 years; hold stock @ target of Rs 755: Praful Bohra, Religare

lio is largely of a commodity generics type; so this will definitely place the company in a strong position in terms of product pipeline in the US market." In a chat with ET Now, Praful Bohra, Religare Capital Markets, talks about Cipla's $550-million ...
 Economic Times10 hours ago
Financial Express

Stocks that are in focus today: Cipla, ONGC, Wipro and more

Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals ...
 Financial Express12 hours ago Stocks that are in focus today: PSU banks, Tata Motors, Cipla and more  Financial Express2 weeks ago Stock in focus today: DLF, Tata Motors and more  Financial Express2 days ago Market report: Sensex recovers 100 points as exporters rally on weak rupee  DNA India2 weeks ago

Cipla's to pay for InvaGen, Exelan mostly through own funds

Cipla Global Chief Executive Officer Subhanu Saxena said both acquisitions would add to Cipla's earnings from Day One, and that the acquisition would give the company a strong platform to accelerate growth in US.
 Money Control12 hours ago Cipla to pay for InvaGen, Exelan mostly through own funds  Money Control6 hours ago

Opening Bell | Cipla, Jyothy Labs, Dr Reddy's in the limelight

Asian markets trade on a cautious note Asian markets were trading on a mixed note on Friday morning as investors waited for the US jobs data which will determine when the Federal Reserve will start increasing interest rates. Hong Kong Hang Seng ...
 Livemint.com13 hours ago Opening Bell | DLF, Jet Airways, ONGC, Oil India in focus  Livemint.com1 day ago Opening Bell | Asian markets extend gains, pharma stocks in focus  Livemint.com1 week ago Opening Bell | R-Com and Jet Airways in limelight  Livemint.com3 weeks ago
India Infoline

Cipla close to buying Hetero's US business: Report

*Password should have 8 to 12 Alphanumeric Characters with one Special Character. Confirm Password I want to create a User ID and have read the terms and conditions for the same Register Now Connect with We encourage visitors to register on IIFL. Registering ...
 India Infoline13 hours ago Cipla stock posts modest gain after Percos deal  India Infoline1 day ago Top M&A news of the day  India Infoline1 day ago Cipla acquires marketing rights of derma player Percos India  Economic Times1 day ago
Business Insider India

Pharma giant Cipla snapped a 2-day losing streak

Join the discussion with Business Insider Refrain from posting comments that are obscene, libellous, slanderous or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. Let's work together to ...
 Business Insider India1 day ago Know how Nifty snapped a 2-day losing streak today  Business Insider India2 weeks ago Stock Market Predictions Nifty likely to consolidate  The Freepress Journal2 weeks ago Here's how the day was at the Markets  Business Insider India3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - cipla
Get updated on latest news & your favorite topics right in your inbox!
More     Less